FDA Courts OpenAI to Turbocharge Drug Reviews—Regulators Scramble to Keep Up

Big Pharma’s new copilot? The FDA is in closed-door talks with OpenAI to deploy AI in drug approval pipelines—while oversight committees wave red flags about black-box algorithms greenlighting your next prescription.

Speed vs. safety: The agency wants ChatGPT-style tech to slash review times, but critics warn of a ’move fast and break patients’ approach. Meanwhile, Wall Street analysts are already pricing in the 300% efficiency bump—because nothing boosts shareholder value like unproven AI and regulatory capture.

Read More

Michaela has no crypto positions and does not hold any crypto assets. This article is provided for informational purposes only and should not be construed as financial advice. The Shib Magazine and The Shib Daily are the official media and publications of the Shiba Inu cryptocurrency project. Readers are encouraged to conduct their own research and consult with a qualified financial adviser before making any investment decisions.